Pharma Focus Asia

Ipsen Completes Acquisition of Albireo

Thursday, March 02, 2023

Ipsen announced it has completed the acquisition of Albireo Pharma. The acquisition enriches Ipsen’s Rare Disease portfolio, with promising therapeutics for paediatric and adult rare cholestatic-liver diseases, innovative pipeline potential, as well as scientific and commercial capabilities. Pursuant to the transaction, Ipsen acquires all the issued and outstanding shares at a price of $42.00 per share in cash plus one non-transferable contingent value right (CVR) of $10.00 per share.

The acquisition of Albireo will greatly strengthen the portfolio of rare diseases and adds novel bile-acid modulators and an innovative pipeline to the existing rare liver portfolio. With Ipsen’s global presence, aims to bring the full potential of the approved medicines to patients around the world.

As part of the transaction, Ipsen has also acquired A3907 and A2342, two clinical-stage assets in Albireo’s pipeline. A3907 is a novel oral systemic apical sodium- dependant bile-acid transporter inhibitor currently in Phase II clinical development for primary sclerosing cholangitis (PSC).3 A2342 is an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor being evaluated for viral and cholestatic diseases in a Phase I trial.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference